Nuvastatic

Nuvastatic is a patented polymolecular botanical medicine derived from a proprietary high-potency ethanolic extract of Orthosiphon stamineus leaves (Lanctos 75). It contains multiple bioactive compounds including rosmarinic acid (6-8% w/w), eupatorine, sinensetin, polysaccharides, glycosaponins, phenolics, flavonoids, and phospholipids. The drug exhibits anti-inflammatory and antiangiogenic properties by targeting key pathways such as NFκB and TNF-α and blocking VEGF signaling. It has demonstrated potential efficacy in reducing cancer-related fatigue in solid tumor patients undergoing chemotherapy as well as antitumor activity against triple-negative breast cancer in preclinical models. Nuvastatic also shows promise for diabetic retinopathy due to its antiangiogenic and neuroprotective effects. Pharmacokinetics studies indicate a half-life of approximately 14.6 hours for rosmarinic acid with metabolism involving liver glucuronidation enzymes UGT1A1 and UGT2B7. The drug is administered orally at doses around 1000 mg thrice daily.

Brand names

Nuvastatic